

# Patricia GassÃ³

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/923728/publications.pdf>

Version: 2024-02-01

44  
papers

748  
citations

567281

15  
h-index

580821

25  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1364  
citing authors

#	ARTICLE	IF	CITATIONS
1	Link between cognitive polygenic risk scores and clinical progression after a first-psychotic episode. <i>Psychological Medicine</i> , 2023, 53, 4634-4647.	4.5	3
2	Gene expression study in monocytes: evidence of inflammatory dysregulation in early-onset obsessive-compulsive disorder. <i>Translational Psychiatry</i> , 2022, 12, 134.	4.8	1
3	The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study. <i>European Neuropsychopharmacology</i> , 2022, 57, 105-117.	0.7	4
4	Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients. <i>NPJ Schizophrenia</i> , 2022, 8, .	3.6	2
5	Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort. <i>Schizophrenia Research</i> , 2022, 244, 101-110.	2.0	8
6	DNA Methylation of Fluoxetine Response in Child and Adolescence: Preliminary Results. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 459-467.	0.7	3
7	Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia. <i>Translational Psychiatry</i> , 2021, 11, 271.	4.8	46
8	Integrative DNA Methylation and Gene Expression Analysis of Cognitive Behavioral Therapy Response in Children and Adolescents with Obsessive-Compulsive Disorder; a Pilot Study. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 757-766.	0.7	3
9	Identification of EP300 as a Key Gene Involved in Antipsychotic-Induced Metabolic Dysregulation Based on Integrative Bioinformatics Analysis of Multi-Tissue Gene Expression Data. <i>Frontiers in Pharmacology</i> , 2021, 12, 729474.	3.5	3
10	A longitudinal study of gene expression in first-episode schizophrenia; exploring relapse mechanisms by co-expression analysis in peripheral blood. <i>Translational Psychiatry</i> , 2021, 11, 539.	4.8	5
11	Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms. <i>Psychopharmacology</i> , 2020, 237, 2151-2159.	3.1	4
12	The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model. <i>Journal of Psychiatric Research</i> , 2020, 126, 8-18.	3.1	9
13	Examining Gene-Environment Interactions Using Aggregate Scores in a First-Episode Psychosis Cohort. <i>Schizophrenia Bulletin</i> , 2020, 46, 1019-1025.	4.3	32
14	Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. <i>Journal of Psychopharmacology</i> , 2020, 34, 514-523.	4.0	12
15	Response to fluoxetine in children and adolescents: a weighted gene co-expression network analysis of peripheral blood. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 2028-2040.	0.0	0
16	Altered frequencies of Th17 and Treg cells in children and adolescents with obsessive-compulsive disorder. <i>Brain, Behavior, and Immunity</i> , 2019, 81, 608-616.	4.1	20
17	Genetic variability in the serotonergic system and age of onset in anorexia nervosa and obsessive-compulsive disorder. <i>Psychiatry Research</i> , 2019, 271, 554-558.	3.3	9
18	Human-leukocyte antigen class II genes in early-onset obsessive-compulsive disorder. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 352-358.	2.6	16

#	ARTICLE	IF	CITATIONS
19	Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics. <i>Translational Psychiatry</i> , 2018, 8, 276.	4.8	12
20	Further Support for the Involvement of Genetic Variants Related to the Serotonergic Pathway in the Antidepressant Response in Children and Adolescents After a 12-Month Follow-Up: Impact of the HTR2A rs7997012 Polymorphism. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 711-718.	1.3	11
21	Modelling gene-environment interaction in first episodes of psychosis. <i>Schizophrenia Research</i> , 2017, 189, 181-189.	2.0	43
22	Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. <i>European Neuropsychopharmacology</i> , 2017, 27, 647-656.	0.7	13
23	Association of regulatory TPH2 polymorphisms with higher reduction in depressive symptoms in children and adolescents treated with fluoxetine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 77, 236-240.	4.8	16
24	Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 75, 28-34.	4.8	28
25	Microarray gene-expression study in fibroblast and lymphoblastoid cell lines from antipsychotic-naïve first-episode schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2017, 95, 91-101.	3.1	12
26	Inflammatory dysregulation of monocytes in pediatric patients with obsessive-compulsive disorder. <i>Journal of Neuroinflammation</i> , 2017, 14, 261.	7.2	42
27	Association of CACNA1C and SYNE1 in offspring of patients with psychiatric disorders. <i>Psychiatry Research</i> , 2016, 245, 427-435.	3.3	9
28	Association between genetic variants of serotonergic and glutamatergic pathways and the concentration of neurometabolites of the anterior cingulate cortex in paediatric patients with obsessive-compulsive disorder. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 394-404.	2.6	10
29	Integrating Genetic, Neuropsychological and Neuroimaging Data to Model Early-Onset Obsessive Compulsive Disorder Severity. <i>PLoS ONE</i> , 2016, 11, e0153846.	2.5	21
30	Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, E46-E55.	2.4	65
31	Pro-/Antiinflammatory Dysregulation in Early Psychosis: Results from a 1-Year Follow-Up Study. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu037-pyu037.	2.1	26
32	Association between genetic variants related to glutamatergic, dopaminergic and neurodevelopment pathways and white matter microstructure in child and adolescent patients with obsessive-compulsive disorder. <i>Journal of Affective Disorders</i> , 2015, 186, 284-292.	4.1	38
33	Applicability of gene expression and systems biology to develop pharmacogenetic predictors; antipsychotic-induced extrapyramidal symptoms as an example. <i>Pharmacogenomics</i> , 2015, 16, 1975-1988.	1.3	11
34	Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial. <i>Pharmacogenomics</i> , 2014, 15, 17-28.	1.3	14
35	Influence of ABO genotype and phenotype on angiotensin-converting enzyme plasma activity. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2014, 15, 580-584.	1.7	18
36	The effect of age on DNA concentration from whole saliva: Implications for the standard isolation method. <i>American Journal of Human Biology</i> , 2014, 26, 859-862.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-naïve first-episode schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2014, 48, 94-101.	3.1	45
38	Relationship between <i>CYP2D6</i> genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers. <i>Pharmacogenomics</i> , 2013, 14, 1551-1563.	1.3	16
39	A common variant of the ABO gene protects against hypertension in a Spanish population. <i>Hypertension Research</i> , 2012, 35, 592-596.	2.7	6
40	Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 71-77.	4.8	47
41	Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients. <i>European Neuropsychopharmacology</i> , 2011, 21, 294-299.	0.7	12
42	Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders. <i>Pharmacogenomics</i> , 2010, 11, 1725-1731.	1.3	12
43	Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes. <i>Psychiatry Research</i> , 2010, 175, 173-175.	3.3	17
44	Association of A/G Polymorphism in Intron 13 of the Monoamine Oxidase B Gene with Schizophrenia in a Spanish Population. <i>Neuropsychobiology</i> , 2008, 58, 65-70.	1.9	21